首页> 美国卫生研究院文献>Journal of Aerosol Medicine and Pulmonary Drug Delivery >The History of Therapeutic Aerosols: A Chronological Review
【2h】

The History of Therapeutic Aerosols: A Chronological Review

机译:治疗性气雾剂的历史:年代学评论

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In 1956, Riker Laboratories, Inc., (now 3 M Drug Delivery Systems) introduced the first pressurized metered dose inhaler (MDI). In many respects, the introduction of the MDI marked the beginning of the modern pharmaceutical aerosol industry. The MDI was the first truly portable and convenient inhaler that effectively delivered drug to the lung and quickly gained widespread acceptance. Since 1956, the pharmaceutical aerosol industry has experienced dramatic growth. The signing of the Montreal Protocol in 1987 led to a surge in innovation that resulted in the diversification of inhaler technologies with significantly enhanced delivery efficiency, including modern MDIs, dry powder inhalers, and nebulizer systems. The innovative inhalers and drugs discovered by the pharmaceutical aerosol industry, particularly since 1956, have improved the quality of life of literally hundreds of millions of people. Yet, the delivery of therapeutic aerosols has a surprisingly rich history dating back more than 3500 years to ancient Egypt. The delivery of atropine and related compounds has been a crucial inhalation therapy throughout this period and the delivery of associated structural analogs remains an important therapy today. Over the centuries, discoveries from many cultures have advanced the delivery of therapeutic aerosols. For thousands of years, therapeutic aerosols were prepared by the patient or a physician with direct oversight of the patient using custom-made delivery systems. However, starting with the Industrial Revolution, advancements in manufacturing resulted in the bulk production of therapeutic aerosol delivery systems produced by people completely disconnected from contact with the patient. This trend continued and accelerated in the 20th century with the mass commercialization of modern pharmaceutical inhaler products. In this article, we will provide a summary of therapeutic aerosol delivery from ancient times to the present along with a look to the future. We hope that you will find this chronological summary intriguing and informative.
机译:1956年,Riker Laboratories,Inc.(现为3 DeliveryM药物输送系统)推出了第一台加压定量吸入器(MDI)。在许多方面,MDI的引入标志着现代制药气雾剂行业的开始。 MDI是第一种真正便携式和便捷的吸入器,可以有效地将药物输送到肺部并迅速获得广泛的接受。自1956年以来,制药气雾剂行业经历了惊人的增长。 1987年《蒙特利尔议定书》的签署导致创新激增,导致吸入器技术多样化,并显着提高了输送效率,包括现代MDI,干粉吸入器和雾化器系统。尤其是自1956年以来,药物气雾剂行业发现了创新的吸入器和药物,从而改善了数以亿计人民的生活质量。然而,治疗性气雾剂的交付具有令人惊讶的丰富历史,其历史可追溯到3500年前的古埃及。在此期间,阿托品和相关化合物的递送一直是至关重要的吸入疗法,而相关结构类似物的递送至今仍是重要的疗法。几个世纪以来,来自许多文化的发现促进了治疗性气雾剂的交付。几千年来,由患者或医师使用定制的输送系统在患者的直接监督下制备了治疗性气雾剂。然而,从工业革命开始,制造的进步导致了治疗性气雾剂输送系统的批量生产,该系统是由与患者完全脱离接触的人们生产的。随着现代药物吸入器产品的大规模商业化,这种趋势在20世纪持续并加速了。在本文中,我们将概述从远古时代到现在的治疗性气雾剂输送以及对未来的展望。我们希望您会发现这份按时间顺序排列的摘要有趣且有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号